Discover Our Latest Resources

Nanomosaic Announced Release of Joint White Paper with BMS Investigating Nanoneedle Technology to Improve AAV Manufacturing Process and Product Quality.

Nanomosaic, the multiplex and multi-omic marker analysis company, today announced major technical and commercial milestones for its Tessie system and assays optimized for gene therapy applications, evidencing the need for improved analytics across development and manufacturing processes.

Successful gene therapy development manufacturing at scale is a matter of ensuring an optimal vector for the genetic material, as well as the integrity of this one, to guarantee the treatment effectiveness. In this Application Note, our team demonstrates how NanoMosaic’s platform allows researchers to obtain high throughputs and a high level of accuracy to characterize capsids and transgenes—all from a single instrument.

Did you miss the chance to book one of our Lunch and Learn sessions this August? No worries! You can still catch up on the "Learn" part!

NanoMosaic's team has developed Tessie, a benchtop reader designed to address the specific challenges of gene therapy manufacturing. Tessie supports the largest gene therapy throughputs, enabling your team to characterize transgenes and capsids using a single instrument and advanced data analysis capabilities.

In this webinar our speakers will introduce NanoMosaic’s Tessie™, a fit-for-purpose platform for gene therapy applications that effectively combines protein and nucleic acid quantification in a single run. During the webinar, they will discuss how Tessie detects and characterizes AAV capsids as well as full, empty, partial, and internally deleted transgenes directly from crude extracts.

WALTHAM, Mass. PRNewswire.